Heron Therapeutics (HRTX) Construction in Progress (2011 - 2025)
Heron Therapeutics' (HRTX) quarterly Construction in Progress came in at $1.7 million in Q4 2025, down 34.62% YoY from $2.6 million in Q4 2024, and down 34.62% on a QoQ basis from $2.6 million in Q4 2024.
Heron Therapeutics (HRTX) Construction in Progress (2011 - 2025) Analysis & Trends
Heron Therapeutics (HRTX) has 13 years of Construction in Progress data on file, last reported at $1.7 million in Q4 2025.
- Quarterly Construction in Progress fell 34.62% year-over-year to $1.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.7 million (down 34.62% YoY) and the FY2025 annual result came in at $1.7 million, down 34.62% from the prior year.
- Construction in Progress eased to $1.7 million in Q4 2025, from $2.6 million in the prior quarter.
- In the past five years, Construction in Progress ranged from a high of $15.9 million in Q4 2021 to a low of $1.7 million in Q4 2025.
- A 5-year average of $6.4 million and a median of $5.4 million in 2022 frame the typical range for Construction in Progress.
- Annual changes were most pronounced in 2022 — Construction in Progress slumped 66.04% — and 2023, when it gained 16.67%.
- Tracing HRTX's Construction in Progress over 5 years: stood at $15.9 million in 2021, then slumped by 66.04% to $5.4 million in 2022, then rose by 16.67% to $6.3 million in 2023, then slumped by 58.73% to $2.6 million in 2024, then tumbled by 34.62% to $1.7 million in 2025.
- The last three Construction in Progress figures came in at $1.7 million (Q4 2025), $2.6 million (Q4 2024), and $6.3 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 152.67 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Heron Therapeutics | 58.32 Mn | 15.65 Mn | 26.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | 2.60 Mn |
| Dec 31, 2023 | 6.30 Mn |
| Dec 31, 2022 | 5.40 Mn |
| Dec 31, 2021 | 15.90 Mn |
| Dec 31, 2020 | 14.10 Mn |
| Dec 31, 2019 | 13.50 Mn |
| Dec 31, 2018 | 10.30 Mn |
| Dec 31, 2017 | 2.00 Mn |
| Dec 31, 2016 | 1.70 Mn |
| Dec 31, 2015 | 200,000.00 |
| Dec 31, 2012 | 777,000.00 |
| Dec 31, 2011 | 718,000.00 |